BioArctic AB
B9A
Company Profile
Business description
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
Contact
Warfvinges vag 35
StockholmSE-112 51
SWET: +46 86956930
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
150
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,735.93 | 75.33 | -0.96% |
| DAX 40 | 25,085.30 | 286.45 | -1.13% |
| Dow JONES (US) | 52,326.31 | 541.67 | -1.02% |
| FTSE 100 | 10,654.39 | 70.64 | -0.66% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 25,912.60 | 96.26 | -0.37% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,624.78 | 38.65 | -0.50% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |